Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
The two companies aim to reduce administrative burden and speed up drug delivery
Read Moreby Esme Needham | Dec 16, 2025 | News | 0
The two companies aim to reduce administrative burden and speed up drug delivery
Read Moreby Jen Brogan | Apr 25, 2024 | News | 0
The tool will help people find out about clinical trials for myeloma, MGUS, SMM and AL amyloidosis
Read Moreby Jen Brogan | Mar 19, 2024 | News | 0
The fatal motor neurone disease currently does not have a cure available to treat patients
Read Moreby Jen Brogan | Feb 12, 2024 | News | 0
The platform delivers digitalised patient data to improve clinical trials and development
Read Moreby Jen Brogan | Oct 9, 2023 | News | 0
The agreement builds on the companies’s existing partnership
Read Moreby John Pinching | Mar 22, 2023 | News | 0
Measures include a requirement to publicly register studies and share results among research participants
Read Moreby John Pinching | Jul 4, 2022 | News | 0
The development is part of company’s mission to support patient access to clinical trials
Read Moreby John Pinching | Apr 20, 2022 | News | 0
Company at the forefront of developing personalised treatments against invasive cancer has raised 15m euros to conduct clinical trials
Read Moreby Iona Everson | Dec 9, 2021 | News | 0
In a new report from The Institute of Cancer Research (ICR), data from cancer trials alongside assessments from clinicians and patients aims to provide guidance on how to improve services
Read Moreby Anna Smith | May 20, 2019 | News | 0
Over 870,250 participants were involved in NIHR supported health and social care studies over the last twelve months.
Read Moreby Anna Smith | Apr 4, 2019 | News | 0
The NIHR’s Dr Jonathan Sheffield gave a positive outlook on UK R&D post-Brexit at the ‘Brexit: What’s Next for Pharma?’ PING conference.
Read Moreby Anna Smith | Jan 24, 2019 | News | 0
Universities that do not improve on fulfilling their legal obligation to report clinical trials over the next six months could be brought in front of the House of Commons Science and Technology Committee to explain why they have failed to do so.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
